Events / Event: Prozac
Event: Prozac
Friday, February 27, 2026 · 3:25 PM ESTEntities: times, dani blum, the new york, prozac, ozempicdani, glp-1
Coverage by Region
Coverage by Institution Type
Articles
AdvertisementSKIP ADVERTISEMENTYou have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.Every once in a while, a new type of medication turns out to be so transformative that it becomes a household name. Take statins, which have prolonged millions of lives by lowering cholesterol. Or Prozac, which revolutionized the treatment of depression.The latest class of drugs to join this club are the GLP-1 receptor agonists. You might know them better by their brand names: Ozempic, Wegovy and Mounjaro. They’ve been hailed as miracle weight-loss drugs that can help people where diet and exercise have failed. There are also a lot of unknowns about the consequences of long-term use.I spoke to my colleague Dani Blum on the Well team to find out how they work and who should — and shouldn’t — take them.ImageCredit...Emily Elconin for The New York TimesWhat we know — and don’t know — about OzempicDani, I’ve known several people who are on Ozempic who lost weight really fast. How exactly do these drugs work?Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe.Related ContentAdvertisementSKIP ADVERTISEMENT